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 Additional sex combs like 1 (ASXL1) is a member of the ASXL family and is involved in epigenetic 
regulation. ASXL1 mutations occur frequently in myeloid neoplasms including myelodysplastic syndromes 
(MDS), chronic myelomonocytic leukaemia (CMML), and acute myeloid leukaemia (AML) and are 
associated with poor prognosis. How ASXL1 mutations induce myeloid transformation is not fully 
understood. Previous studies have reported that ASXL1 knockdown and genetic deletion of Asxl1 in 
haematopoietic cells promotes myeloid transformation, indicating that mutations in ASXL1 produce loss 
of function. However, a growing body of evidence suggests that ASXL1 mutations in fact result in gain of 
function. Experiments using mouse bone marrow transplantation models have revealed that forced 
expression of a C-terminally truncated ASXL1 mutant in haematopoietic progenitor cells induces MDS-
like diseases, and accelerates AML development in concert with Nras or SETBP1 mutations. In patients 
with ASXL1 mutations, the mutations are typically heterozygous and occur near the 5′ end of exon 12, thus 
producing C-terminally truncated ASXL1 proteins are indeed expressed in MDS cells. Thus, whether 
ASXL1 mutations promote myeloid transformation via a gain- or loss-of-function remains an unresolved 
question.   
In the present study, I found a mutually reinforcing effect between a C-terminally truncating 
ASXL1 mutant (ASXL1-MT) and the histone H2A deubiquitinase Brca-1 associated protein 1 (BAP1). I 
revealed that BAP1 strongly stabilized ASXL1-MT, but not wildtype ASXL1 and induced its 
monoubiquitination at lysine 351. The monoubiquitinated ASXL1-MT in turn enhanced the catalytic 
function and nuclear retention of BAP1. Thus, ASXL1-MT forms a hyperactive complex with BAP1 and 
removes efficiently global ubiquitination from histone H2A at lysine 119 (H2AK119ub) in cells. 
I next assessed the role of ASXL1-MT and BAP1 in hematopoietic differentiation using in vitro 
cell culture assays with cell lines (32Dcl3 and TF1), mouse primary bone marrow (BM) cells, and human 
primary CD34+ cord blood (CB) cells. These assays revealed that ASXL1-MT alone moderately, and 
coexpression of ASXL1-MT and BAP1 dramatically impaired differentiation of hematopoietic 
stem/progenitor cells towards granulocytes, macrophages, mast cells, and matured erythroid cells. 
Interestingly, ASXL1-MT/BAP complex did not inhibit, but rather promoted monocytic differentiation, 
which may account for the frequent detection of ASXL1 mutations in patients with chronic myelomonocytic 
leukemia (CMML).  
I then assessed the role of ASXL1-MT and BAP1 in myeloid leukemogenesis. Coexpression of 
ASXL1-MT and BAP1 enhanced colony forming capacity of mouse BM cells, but was not sufficient to 
immortalize them. Next, I examined the potential cooperation between ASXL1-MT and RUNX1-ETO in 
promoting myeloid leukemogenesis because ASXL1 mutations have been frequently found in RUNX1-ETO 
leukemia patients. Forced expression of ASXL1-MT significantly accelerated the development of leukemia 
driven by RUNX1-ETO9a (a shorter isoform of RUNX1-ETO with a strong leukemogenic activity) in a 
mouse BM transplantation model, and also promoted the growth of RUNX1-ETO-expressing human CB 
cells in vitro. These growth-promoting effects of ASXL1-MT were further enhanced by BAP1 coexpression 
in RUNX1-ETO leukemia cells. Thus, ASXL1-MT/BAP1 complex promotes myeloid leukemogenesis in 
cooperation with RUNX1-ETO. 
Mechanistically, I identified posterior HOXA cluster genes and IRF8 as direct targets of 
ASXL1-MT/BAP1 complex. RNA-seq analysis and ChIP-qPCR assays revealed that ASXL1-MT/BAP1 
complex bound to the promoter regions of Hoxa5, Hoxa7, Hoxa9, and Irf8 genes, and induced upregulation 
of these genes through removal of H2AK119ub. The upregulation of posterior HOXA genes and IRF8 likely 
contribute to the ASXL1-MT/BAP1-induced leukemogenesis and monopoiesis, respectively.   
Finally, I performed endogenous Bap1 depletion using CRISPR/Cas9 system in murine 
leukemia cells transformed by combined expression of ASXL1-MT and a SETBP1 mutant (SETBP1-
D868N). Strikingly, Bap1 depletion in the cells dramatically reduced leukemogenicity. In addition, Bap1 
depletion decreased posterior Hoxa gene expression in the cells. I then examined whether Bap1 is also 
required for leukemogenicity of MLL-fusion leukemia, a well-known leukemia subtype characterized by 
Hox gene dysregulation. Again, Bap1 depletion profoundly reduced colonogenicity and posterior Hoxa 
gene expression in mouse BM cells transformed by MLL-AF9. I also confirmed the critical roles of 
endogenous BAP1 to support the growth of human myeloid leukemia cell lines with ASXL1 mutations 
(Kasumi-1, MEG-01 and TS9;22) or MLL-fusions (MOLM-13 and THP1).  
In summary, my study demonstrated the critical role of BAP1 in ASXL1-MT-induced aberrant 
myeloid differentiation, myeloid leukemogenesis via upregulation of HOXA genes and IRF8. Targeting 
enzymatic activity of BAP1, which has long been considered a tumor suppressor, can be a promising 
therapeutic strategy for myeloid neoplasms with ASXL1 mutations, and potentially for a broad range of 
myeloid neoplasms with HOX dysregulation. 
